GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (FRA:R9M) » Definitions » Notes Receivable

Myrexis (FRA:R9M) Notes Receivable : €0.00 Mil (As of Jun. 2013)


View and export this data going back to . Start your Free Trial

What is Myrexis Notes Receivable?

Myrexis's Notes Receivable for the quarter that ended in Jun. 2013 was €0.00 Mil.


Myrexis Notes Receivable Historical Data

The historical data trend for Myrexis's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myrexis Notes Receivable Chart

Myrexis Annual Data
Trend Jun08 Jun09 Jun10 Jun11 Jun12 Jun13
Notes Receivable
Get a 7-Day Free Trial - - - - -

Myrexis Quarterly Data
Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Myrexis Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Myrexis Notes Receivable Related Terms

Thank you for viewing the detailed overview of Myrexis's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Myrexis (FRA:R9M) Business Description

Traded in Other Exchanges
N/A
Address
630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020
Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.

Myrexis (FRA:R9M) Headlines

No Headlines